FeesSafety
Pluang+

Xtant Medical reports Q3 revenue decline but sees growth in core biologics; strategic review underway to boost value.

Company Fundamentals
16 Nov 2026, 14:00 WIB
PRNewsWire
View Source
Bearish
Xtant Medical reports Q3 revenue decline but sees growth in core biologics; strategic review underway to boost value.

Xtant Medical Holdings reported a Q3 2026 revenue of $24.3 million, down from $33.3 million in Q3 2025, mainly due to divested businesses and lost wound care licensing revenue. However, biologics revenue grew 13% year-over-year, showing momentum in the core business. The Board expressed disappointment over missing financial targets for two consecutive quarters and is conducting a strategic review to improve performance and maximize stockholder value. The company expects current cash and credit availability to fund operations for at least 12 months but has withdrawn its full-year 2026 guidance amid this review.

Xtant Medical's Q3 2026 financial results provide context for readers. For those tracking the health sector, here is Pluang's market snapshot as of Nov 16, 2026 18:12 WIB: out of 150 priced health-sector US stocks, 66 rose and 50 fell. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 8.80 with a 1-day change of +3.77%, Brookdale Senior Living Inc. (BKD) at USD 8.85 with -3.49%, and Guardant Health Inc. (GH) at USD 147.01 with -3.18%.

More News

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
19 minutes ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
19 minutes ago
Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo Inc. announced the renewal of its normal course issuer bid, allowing it to repurchase up to 22.5 million ordinary shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's ongoing c...

Company Fundamentals
Bullish
19 minutes ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
1 hour ago
Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App